pancreatic acinar cell adenocarcinoma
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:5742
Name pancreatic acinar cell adenocarcinoma
Definition A pancreatic adenocarcinoma that has_material_basis_in cells with morphological resemblance to acinar cells and is associated with increased serum lipase.
Source DiseaseOntology.org
Alt Ids
Xrefs
SNOMEDCT_US_2023_03_01:783771003
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer pancreatic carcinoma pancreatic adenocarcinoma pancreatic acinar cell adenocarcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E Dabrafenib + Trametinib pancreatic acinar cell adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01537107 Phase I Sirolimus + Vismodegib Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery Completed USA 0
NCT02834013 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT03412799 Phase I Gemcitabine + Nab-paclitaxel + SBP-101 Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer Completed USA | AUS 0
NCT04858334 Phase II Olaparib APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation Recruiting USA | ISR 1
NCT05286827 Phase II Olaparib Phase II Study of Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma Active, not recruiting USA 0
NCT06813079 Phase II Abemaciclib Ceritinib Selinexor Doxorubicin Etoposide Brigatinib Ponatinib Neratinib Cobimetinib Using Tumor Models to Determine Treatments Not yet recruiting CAN 0